|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.130 USD | 0.00% |
|
+7.62% | -67.99% |
| 06-30 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 06-30 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
Company Valuation: ADC Therapeutics SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,550 | 306.9 | 134.1 | 192.4 | 437.3 | 143.7 | - | - |
| Change | - | -80.2% | -56.31% | 43.49% | 127.27% | -67.13% | - | - |
| Enterprise Value (EV) | 1,092 | 90.22 | -20.12 | 192.4 | 437.3 | 143.7 | 143.7 | 143.7 |
| Change | - | -91.74% | -122.31% | 1,056.12% | 127.27% | -67.13% | 0% | 0% |
| P/E | -6.73x | -1.93x | -0.56x | -1.23x | -3.15x | -1.32x | -1.71x | -20.5x |
| PBR | 9.34x | 3.49x | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | 0x | 0.1x | 0.1x | 0.1x | 0.2x |
| Capitalization / Revenue | 45.7x | 1.46x | 1.93x | 2.72x | 5.37x | 1.78x | 1.16x | 0.56x |
| EV / Revenue | 0x | 0x | -0x | 0x | 0x | 1.78x | 1.16x | 0.56x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | -0x | -1.51x | -2.22x | 3.11x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3 | -1.99 | -2.94 | -1.62 | -1.12 | -0.856 | -0.6625 | -0.055 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 33.92 | 209.9 | 69.56 | 70.84 | 81.36 | 80.89 | 123.8 | 254.4 |
| EBITDA | -198.6 | -71.98 | - | - | - | - | - | - |
| EBIT 1 | -261.7 | -123.6 | -166 | -130.7 | -121.5 | -94.97 | -64.85 | 46.14 |
| Net income 1 | -230 | -155.8 | -240.1 | -157.8 | -142.6 | -136.1 | -117.3 | -7.638 |
| Net Debt | -458.5 | -216.7 | -154.2 | - | - | - | - | - |
| Reference price 2 | 20.200 | 3.840 | 1.660 | 1.990 | 3.530 | 1.130 | 1.130 | 1.130 |
| Nbr of stocks (in thousands) | 76,754 | 79,934 | 80,781 | 96,690 | 123,877 | 127,191 | - | - |
| Announcement Date | 3/3/22 | 2/28/23 | 3/13/24 | 3/27/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.32x | - | - | - | 144M | |
| 20.56x | 7.11x | 14.62x | 1.42% | 68.12B | |
| 31.44x | 8.03x | 24.45x | 0.05% | 55.18B | |
| -82.4x | 15.59x | -64.97x | -.--% | 28.63B | |
| 30.46x | 5.97x | 15.8x | -.--% | 23.99B | |
| -14.71x | 5.23x | -6.82x | -.--% | 23.53B | |
| 25.47x | 4.76x | 15.94x | -.--% | 18.45B | |
| -1250.29x | 38.99x | -15519.34x | -.--% | 16.44B | |
| 47.61x | 19.33x | 49.78x | 0.08% | 15.83B | |
| 16.76x | 4.95x | 11.57x | -.--% | 13.4B | |
| Average | -117.64x | 12.22x | -1,717.66x | 0.17% | 26.37B | |
| Weighted average by Cap. | -68.04x | 10.40x | -960.50x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ADCT Stock
- Valuation ADC Therapeutics SA
Select your edition
All financial news and data tailored to specific country editions
